Actinium Pharmaceuticals Inc., of New York, underwent a 1-for-30 reverse stock split after trading closed on Monday. Shares of Actinium (NYSE AMERICAN:ATNM) closed at $9.66, down $2.04, or 17.4%, on a reverse split basis on Aug. 11.
Altitude Lab, of Salt Lake City, a new 14,500-square-foot incubator founded by Recursion and the University of Utah’s Center for Technology & Venture Commercialization, will initially house Known Med, 3Helix and Nexeos Bio. The incubator, which is scheduled to open its wet lab facility in October, is accepting applications for additional residents.
Amydis Inc., of San Diego, received a grant from The Michael J. Fox Foundation (MJFF) for Parkinson’s Research to support its retinal tracer program for alpha-synuclein. The company received a grant from MJFF in 2018 to support development of retinal tracers for Parkinson’s disease.
Ana Therapeutics, of Foster City, Calif., and Quotient Sciences Ltd., of Nottingham, U.K., are collaborating to manufacture Ana’s ANA-001 (niclosamide) as a treatment for COVID-19. Quotient will manufacture the capsules at its facility in Garnet Valley, Pa., to support a pivotal clinical trial scheduled to begin in the third quarter of 2020.
Appili Therapeutics Inc., of Halifax, Nova Scotia, said shares of the company, which trade in the U.S. under the symbol APLIF, are Depository Trust Company eligible. Depository Trust & Clearing Corp. will manage the electronic clearing and settlement of the shares, which will also continue to trade on the TSX Venture Exchange.
Aum Lifetech, Inc., of Philadelphia, received a $600,000 Small Business Innovation Research Grant from the U.S. National Institute of Allergy and Infectious Diseases to support Aum’s preclinical HIV program that targets RNA of HIV to inhibit replication.
Beyond Air Inc., of Garden City, N.Y., reported results from a compassionate use case study using its inhaled nitric oxide (NO) to treat pulmonary Mycobacterium abscessus disease in a 24-year-old, female cystic fibrosis patient with chronic and progressive pulmonary M. abscessus at the U.S. National Heart, Lung, and Blood Institute. The patient noted improved respiratory symptoms and quality of life and had small improvements in her lung function, six-minute walk distance and inflammatory markers but no significant change in tests and cultures for M. abscessus. Patient requested to repeat treatment; however, dosing at 240 ppm was stopped after day eight of retreatment due to adverse events, which did not occur during administration of NO, and methemoglobin levels remained within safe thresholds at all times. Data were published in Access Microbiology.
Beyondspring Inc., of New York, started an expanded access program for plinabulin for the prevention of chemotherapy-induced neutropenia (CIN) in patients with cancer. The National Comprehensive Cancer Network recently updated its guidelines to focus on reducing CIN during the COVID-19 pandemic.
Biostem Technologies Inc., of Pompano Beach, Fla., said its subsidiary, Blue Tech Industries Inc., signed an agreement with a new customer to manufacture the undisclosed customer’s amniotic membrane platform for the next two years. The deal, which is worth up to $2.4 million, also allows the companies to establish additional projects in the future.
Bridgebio Pharma Inc., of Palo Alto, Calif., is partnering with Shanghai-based Lianbio, which was recently founded by Perceptive Advisors, to expand into China. The partnership will initially focus on FGFR inhibitor infigratinib and SHP2 inhibitor BBP-398 in China and selected Asian markets. The deal also includes preferential future access in the territory to more than 20 drug development candidates that Bridgebio currently owns or controls. Bridgebio is eligible for $26.5 million in up-front and near-term milestone payments as well as up to $505 million in future milestone payments and tiered royalty payments from single- to double-digits on net sales of both products in licensed territories. As part of the deal, Bridgebio is making an equity investment in Lianbio.
Caris Life Sciences, of Irving, Texas, and New York-based Elevation Oncology Inc. are collaborating to improve enrollment in Elevation’s phase II Crestone study in patients with neuregulin-1 fusion-positive tumors.
Chrysalis Biotherapeutics Inc., of Galveston, Texas, said the U.S. National Institute of Allergy and Infectious Diseases provided additional funding in the amount of $587,995 to its contract with Chrysalis, bringing the total award to $1.5 million for development of TP-508 as a COVID-19 therapeutic. Funding will be used to complete in vivo testing, drug manufacturing and regulatory steps for initiation of clinical trials. TP-508 (rusalatide acetate) has shown an ability to restore endothelial function and reduce the effects of inflammation in animal studies.
Evotec SE, of Hamburg, Germany, licensed a preclinical broad-spectrum antibiotic program from Resolute Therapeutics Inc., of Winston Salem, N.C. Evotec has received a commitment for an award of up to $2.91 million over the next two years from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Evotec is eligible for an additional $5.53 million from CARB-X over the three following years if certain project milestones are met.
Eyenovia Inc., of New York, licensed the rights to Micropine, a treatment for progressive myopia, and Microline, a treatment for presbyopia, in greater China to Shanghai-based Arctic Vision Biotechnology Co. Ltd. Eyenovia is eligible for up to $45.75 million in up-front and future payments based on meeting development and regulatory milestones. Eyenovia will supply the products to Arctic Vision or will be eligible for a mid-single-digit percentage royalty on net sales of products not acquired by Arctic Vision.
Hemogenyx Pharmaceuticals plc, of London, signed an agreement with the University of Pennsylvania to advance HEMO-CAR-T toward clinical trials with a goal of continuing the program through a proof-of-concept study for HEMO-CAR-T as a treatment for acute myeloid leukemia.
Innate Pharma Sa, of Marseille, France, obtained €6.8 million (US$7.98 million) under the French government’s PSPC-COVID program to support preventive or curative treatments for COVID-19. Innate plans to use the capital to fund its Explore translational research study and two phase II studies: Force and Immunoncovid-20. The company will receive the money in four equal tranches with 80% of each tranche requiring reimbursement upon technical and commercial success.
Janone Inc., of Las Vegas, and its manufacturing partner completed formulation of JAN-101, which will enter a phase IIb study in peripheral artery disease soon. The company also plans to study the drug in patients with COVID-19 vascular complications after the submission of an IND, which is expected to be completed in late August 2020.
Ligand Pharmaceuticals Inc., of San Diego, is acquiring Pfenex Inc., also of San Diego, for $12 per share in cash, or $438 million. Pfenex’s investors will also receive a contingent value right that’s eligible for $2 per share if a predefined regulatory milestone is achieved by Dec. 31, 2021. The transaction is expected to close in the fourth quarter of 2020. Shares of Pfenex (NASDAQ:PFNX) jumped $5.17, or 67%, to close Aug. 11 at $12.83, while shares of Ligand (NASDAQ:LGND) closed at $111.90, down $6.76.
Molecular Partners Ag, of Zurich-Schlieren, Switzerland, said the Swiss Federal Office of Public Health: Bundesamt für Gesundheit reserved 200,000 doses of its COVID-19 candidate, MP-0420. The government also has the option to purchase up to an additional 3 million doses. Molecular Partners will receive a reservation fee in the high single-digit millions Swiss Francs. The company plans to start clinical studies of the drug in the fourth quarter of 2020.
Nascent Biotech Inc., of San Diego, reduced its liabilities by converting $1.6 million in debt to equity. The company also paid off more than $200,000 in liabilities.
Revive Therapeutics Ltd., of Toronto, received the first set of orally dissolvable thin film strips to be used to deliver psilocybin and additional psychedelic-derived medicines as part of its partnership with the University of Wisconsin-Madison.
Saillant Therapeutics, of Nijmegen, the Netherlands, disclosed a virus-inhibiting treatment platform based on activation of a cellular master regulator. The mode of action works against a wide range of viruses, including those that cause COVID-19, dengue, Zika and Ebola. The company is working on new formulations of the reference substance with plans to start clinical trials within one to two years.
Sapphire Biotech Inc., a subsidiary of San Diego-based Axim Biotechnologies Inc., was awarded a $395,880 phase I Small Business Innovation Research grant by the U.S. National Cancer Institute. The company will use the capital to further develop small molecules that inhibit the enzymatic activity of quiescin sulfhydryl oxidase I, which is associated with cancer growth, invasion and metastasis.
Sarepta Therapeutics Inc., of Cambridge, Mass., and the University of Florida are collaborating to enable research for genetic medicines. Under the terms, Sarepta will fund multiple research programs at the university, and will have an exclusive option to further develop any new therapeutic compounds that result from the funded research programs. Funding has been allocated for four projects, including exploratory research in gene therapy vectors, next-generation capsids and gene editing technologies as well as work in new therapeutic areas in degenerative genetic diseases.
Tevogen Bio Inc., of Metuchen, N.J., said it entered a joint partnership with bone marrow transplant expert Neal Flomenberg, professor and chair of the Department of Medical Oncology at Thomas Jefferson University, with the intent to evaluate Tevogen' s antigen-specific T-cell technology as a potential treatment for COVID-19 and influenza-A patients.